- Home
- STSS
as 06-06-2025 4:00pm EST
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MELVILLE |
| Market Cap: | 4.6M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -399.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.36 - $2904.00 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Sharps Technology Inc. News
STSS Breaking Stock News: Dive into STSS Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
Top Midday Gainers
MT Newswires
3 days ago
Sharps Technology Begins First Shipments of Smart Safety Syringes For 3 Client Orders; Shares Up Pre-Bell
GlobeNewswire
3 days ago
Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements
MT Newswires
16 days ago
Sharps Technology Regains Compliance With Nasdaq Requirements
GlobeNewswire
16 days ago
Sharps Technology Regains Compliance with Nasdaq Minimum Bid Price Listing Rule
GlobeNewswire
17 days ago
Sharps Technology to Present at the Aegis Capital Corp. 2025 Virtual Conference on May 22nd
GlobeNewswire
a month ago
Sharps Technology Receives ~$100K Initial Purchase Order from Hungarian Vaccine Provider for SecureGard™ Syringes
GlobeNewswire
a month ago
Sharps Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement
Compare STSS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STSS Sharps Technology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.